Tibolone and the promise of ideal hormone-replacement therapy

New England Journal of Medicine

Volumn 359, Issue 7, 2008, Pages 753-755

  El Hajj Fuleihan, Ghada ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

CITRATE CALCIUM; ESTROGEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TIBOLONE; VITAMIN D;

AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; BREAST DISEASE; CANCER RISK; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFECT; DRUG SAFETY; EDITORIAL; FRAGILITY FRACTURE; HORMONE SUBSTITUTION; HUMAN; INFECTION; LIFE EXPECTANCY; MENOPAUSAL SYNDROME; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; RISK; SIDE EFFECT; STROKE; VAGINA DISCHARGE; WOMEN'S HEALTH;

ANDROGEN ANTAGONISTS; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; NORPREGNENES; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; SPINAL FRACTURES;

EID: 49449086847     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe0805175     Document Type: Editorial

References (16)

1. Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep 2008;56(10):1-120.
2. Hickey M, Davis SR, Sturdee DW. Treatment of menopausal symptoms: what shall we do now? Lancet 2005;366:409-21.
3. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
4. Kloosterboer HJ, Ederveen AG. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (±progestogen) treatments. J Steroid Biochem Mol Biol 2002;83:157-65.
5. Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697-708.
6. Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 2002;87:16-23.
7. Rosen CJ. Postmenopausal osteoporosis. N Engl J Med 2005;353:595-603.
8. Campisi R, Marengo FD. Cardiovascular effects of tibolone: a selective tissue estrogenic activity regulator. Cardiovasc Drug Rev 2007;25:132-45.
9. Bots ML, Evans GW, Riley W, et al. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intimamedia thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. Eur Heart J 2006;27:746-55.
10. Mols M. Tibolone study in breast cancer patients to close ahead of schedule. Auckland, New Zealand: Drugs.com. (Accessed July 25, 2008, at http://drugs.com/news/tibolone-studybreast-cancer-patients-close-ahead-schedule- 6164.html.)
11. Langer RD, Landgren BM, Rymer J, Helmond FA. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study. Am J Obstet Gynecol 2006;195:1320-7.
12. Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab 2007;92:911-8.
13. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27. [Erratum, Lancet 2003;362:1160.]
14. Idem. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-51.
15. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77. [Erratum, JAMA 2008;299:1426.]
16. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-45.